Long-term treatment outcomes with lisdexamfetamine dimesylate for adults with attention-deficit/hyperactivity disorder stratified by baseline severity

References

• Greenhill LL, Pliszka S, Dulcan MK, et al. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 2002;41(2 Suppl):26-49S
   PubMed Web of Science ®Google Scholar
• Dulcan M, and the Work Group on Quality Issues. Practice parameters for the assessment and treatment of children, adolescents, and adults with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1997;36:85-121S
   PubMed Web of Science ®Google Scholar
• Kessler RC, Adler LA, Barkley R, et al. Patterns and predictors of attention-deficit/hyperactivity disorder persistence into adulthood: results from the National Comorbidity Survey Replication. Biol Psychiatry 2005;57:1442-51
   PubMed Web of Science ®Google Scholar
• Lara C, Fayyad J, De Graaf R, et al. Childhood predictors of adult attention-deficit/hyperactivity disorder: results from the World Health Organization World Mental Health Survey Initiative. Biol Psychiatry 2009;65:46-54
   PubMed Web of Science ®Google Scholar
• Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry 2006;163:716-23
   PubMed Web of Science ®Google Scholar
• Biederman J, Faraone SV, Spencer TJ, et al. Functional impairments in adults with self-reports of diagnosed ADHD: a controlled study of 1001 adults in the community. J Clin Psychiatry 2006;67:524-40
   PubMed Web of Science ®Google Scholar
• Biederman J, Petty CR, Fried R, et al. Educational and occupational underattainment in adults with attention-deficit/hyperactivity disorder: a controlled study. J Clin Psychiatry 2008;69:1217-22
   PubMed Web of Science ®Google Scholar
• Able SL, Johnston JA, Adler LA, et al. Functional and psychosocial impairment in adults with undiagnosed ADHD. Psychol Med 2007;37:97-107
   PubMed Web of Science ®Google Scholar
• Sobanski E. Psychiatric comorbidity in adults with attention-deficit/hyperactivity disorder (ADHD). Eur Arch Psychiatry Clin Neurosci 2006;256(Suppl 1):i26-31
   PubMed Web of Science ®Google Scholar
• Frank E, Prien RF, Jarrett RB, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 1991;48:851-5
   PubMed Web of Science ®Google Scholar
• Landgraf JM. Monitoring quality of life in adults with ADHD: reliability and validity of a new measure. J Atten Disord 2007;11:351-62
   PubMedGoogle Scholar
• Adler LA, Spencer TJ, Levine LR, et al. Functional outcomes in the treatment of adults with ADHD. J Atten Disord 2008;11:720-7
   PubMed Web of Science ®Google Scholar
• Escobar R, Montoya A, Polavieja P, et al. Evaluation of patients' and parents' quality of life in a randomized placebo-controlled atomoxetine study in attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2009;19:253-63
   PubMed Web of Science ®Google Scholar
• Thiruchelvam D, Charach A, Schachar RJ. Moderators and mediators of long-term adherence to stimulant treatment in children with ADHD. J Am Acad Child Adolesc Psychiatry 2001;40:922-8
   PubMed Web of Science ®Google Scholar
• Taylor E, Schachar R, Thorley G, et al. Which boys respond to stimulant medication? A controlled trial of methylphenidate in boys with disruptive behaviour. Psychol Med 1987;17:121-43
   PubMed Web of Science ®Google Scholar
• Denney CB, Rapport MD. Predicting methylphenidate response in children with ADHD: theoretical, empirical, and conceptual models. J Am Acad Child Adolesc Psychiatry 1999;38:393-401
   PubMed Web of Science ®Google Scholar
• Steele M, Jensen PS, Quinn DMP. Remission versus response as the goal of therapy in ADHD: a new standard for the field?. Clin Ther 2006;28:1892-908
   PubMed Web of Science ®Google Scholar
• Nierenberg AA, DeCecco LM. Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression. J Clin Psychiatry 2001;62(Suppl 16):5-9
   PubMedGoogle Scholar
• Keck PE Jr, McElroy SL, Strakowski SM, et al. 12-month outcome of patients with bipolar disorder following hospitalization for a manic or mixed episode. Am J Psychiatry 1998;155:646-52
   PubMed Web of Science ®Google Scholar
• Biederman J, Mick E, Faraone SV. Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type. Am J Psychiatry 2000;157:816-8
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders DSM-III-R. 3rd edn. Washington, DC: American Psychiatric Association, 1987
   Google Scholar
• Stein MA. Innovations in attention-deficit/hyperactivity disorder pharmacotherapy: long-acting stimulant and nonstimulant treatments. Am J Manag Care 2004;10(Suppl):S89-98
   Web of Science ®Google Scholar
• Faraone SV. Lisdexamfetamine dimesylate: the first long-acting prodrug stimulant treatment for attention deficit/hyperactivity disorder. Expert Opin Pharmacother 2008;9:1565-74
   PubMed Web of Science ®Google Scholar
• Adler LA, Goodman DW, Kollins SH, et al, on behalf of the 303 Study Group. Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2008;69:1364-73
   PubMed Web of Science ®Google Scholar
• Wigal T, Brams M, Gasior M, et al.; on behalf of the 316 Study Group. Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using the adult workplace environment design. Behav Brain Funct 2010;6:34
   PubMed Web of Science ®Google Scholar
• Weisler R, Young J, Mattingly G, et al.; on behalf of the 304 Study Group. Long-term safety and effectiveness of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. CNS Spectr 2009;14:573-85
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Attention-deficit and disruptive behavior disorders. In: Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR, 4th edn. Text Revision. Washington, DC: American Psychiatric Association, 2000
   Google Scholar
• Adler L, Cohen J. Diagnosis and evaluation of adults with attention-deficit/hyperactivity disorder. Psychiatr Clin North Am 2004;27:187-201
   PubMed Web of Science ®Google Scholar
• Guy W. Clinical global impressions. In: ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Health, Education, and Welfare; Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, 1976:218–22
   Google Scholar
• Young J, Mattingly G, Weisler R, et al. Response and symptomatic remission in a long-term trial of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. Poster presented at: American Psychiatric Association’s 162nd Annual Meeting; May 16–21, 2009; San Francisco, CA, USA
   Google Scholar
• Swanson JM, Kraemer HC, Hinshaw SP, et al. Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment. J Am Acad Child Adolesc Psychiatry 2001;40:168-79
   PubMed Web of Science ®Google Scholar
• Mattingly G, Weisler R, Young J, et al. Response and symptomatic remission in short- and long-term trials of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. Poster presented at: US Psychiatric and Mental Health Congress Conference and Exhibition; November 2–5, 2009; Las Vegas, NV, USA
   Google Scholar
• Stein MA, Sarampote CS, Waldman ID, et al. A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 2003;112:e404-13
   PubMed Web of Science ®Google Scholar
• Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 2002;159:1896-901
   PubMed Web of Science ®Google Scholar
• Kelsey DK, Sumner CR, Casat CD, et al. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics 2004;114:e1-8
   PubMed Web of Science ®Google Scholar
• Swanson J, Lerner M, March J, et al. Assessment and intervention for attention-deficit/hyperactivity disorder in the schools. Lessons from the MTA study. Pediatr Clin North Am 1999;46:993-1009
   PubMed Web of Science ®Google Scholar
• Ginsberg LD, Schreckengost J, Krishnan S. Effect of lisdexamfetamine dimesylate on parent-rated measures of attention-deficit/hyperactivity disorder (ADHD) in children aged 6 to 12 years with ADHD: A Secondary Analysis. Poster presented at: 20th Annual U.S. Psychiatric and Mental Health Congress; October 11–14, 2007; Orlando, FL
   Google Scholar
• Leucht S, Davis JM, Engel RR, et al. Definitions of response and remission in schizophrenia: recommendations for their use and their presentation. Acta Psychiatr Scand Suppl 2009;119:7-14
   Google Scholar
• Barkley RA, Murphy KR. Impairment in occupational functioning and adult ADHD: the predictive utility of executive function (EF) ratings versus EF tests. Arch Clin Neuropsychol 2010;25:157-73
   PubMed Web of Science ®Google Scholar
• Sciberras E, Roos LE, Efron D. Review of prospective longitudinal studies of children with ADHD: mental health, educational, and social outcomes. Curr Atten Disord Report 2009;1:171-7
   Google Scholar